Mersana Therapeutics

Mersana develops next-generation ADCs with novel payloads and linkers, including Dolasynthen and Immunosynthen platforms. Their work emphasises tolerability and new targets. Compared with Valink, Mersana has more disclosed clinical assets while Valink's LiliumX AI engine and V-Gate logic provide a differentiated discovery approach for bispecific constructs.